Literature DB >> 3510263

Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

A U Gerber, H P Brugger, C Feller, T Stritzko, B Stalder.   

Abstract

An effort was made to elucidate the limits of drug-activity tests in small animals. Human plasma kinetics of gentamicin, netilmicin, ticarcillin, ceftazidime, and ceftriaxone were approximated in normal and in granulocytopenic mice infected with various strains of Pseudomonas aeruginosa in the thigh muscle or intraperitoneally. The effect of such dosing on bacterial time-kill curves and on survival was compared with the effect of identical amounts of drug given as a single-bolus injection. With beta-lactams, a highly significant superiority of fractionated dosing (simulated human kinetics) over bolus injections (murine plasma kinetics) was demonstrated, whereas with aminoglycosides it was a single-bolus injection that tended to be more active. Thus, when tested in conventional small-animal models, aminoglycoside activity may be overestimated, whereas beta-lactam activity may be underestimated in respect to humans. These differences found in vivo most probably reflect the different pharmacodynamics between aminoglycosides and beta-lactam drugs (time-kill curves, dose-response curves, and postantibiotic effect) similar to those previously observed in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510263     DOI: 10.1093/infdis/153.1.90

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  55 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.

Authors:  J Berkhout; L G Visser; P J van den Broek; J A M van de Klundert; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 4.  Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.

Authors:  A Dalhoff; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

5.  Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.

Authors:  Fekade Bruck Sime; Michael S Roberts; Morgyn S Warner; Uwe Hahn; Thomas A Robertson; Sue Yeend; Andy Phay; Sheila Lehman; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  Peptides related to the carboxyl terminus of human platelet factor IV with antibacterial activity.

Authors:  R P Darveau; J Blake; C L Seachord; W L Cosand; M D Cunningham; L Cassiano-Clough; G Maloney
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Animal models in the evaluation of antimicrobial agents.

Authors:  O Zak; T O'Reilly
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

9.  Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due to Escherichia coli in rats.

Authors:  E Vieler; C Jantos; H L Schmidts; W Weidner; H G Schiefer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.